Drug pharmacokinetics of antimicrobial agents is significantly altered in the burn patients.
Additionally, burn patient population exhibits a wide inter- and intrapatient variation in
drug handling. Several investigations carried out in burn patients treated with e.g.
fluconazole showed the requirement to increase daily dose in comparison with healthy
volunteers. However, no pharmacokinetic data are available of caspofungin in the burn
population. The aim of this investigation is to investigate pharmacokinetics of caspofungin
in burn patients after a single usual dose (70 mg i.v.), in order to determine the optimal
dose in this population.